Compound reference

KLOW Dosage Guide 2026: What Is Actually In the Vial

By the Decadewise team Education only Last reviewed 19 July 2026 7 cited sources

Short answer

What it is: KLOW is a grey-market peptide blend, most often an 80mg vial combining four compounds: GHK-Cu 50mg, KPV 10mg, BPC-157 10mg, TB-500 10mg on the common label.

The trial doses: none exist. No human study has ever tested the KLOW blend.

GHK-Cu: copper tripeptide, human data topical and thin
TB-500: thymosin beta-4 fragment, no human exposure data per FDA
BPC-157: gastric pentadecapeptide, almost entirely preclinical
KPV: melanocortin tripeptide, mouse colitis models

The headline number: zero published studies on the blend itself, against a SERP full of confident protocol pages.

The catch: those pages disagree. One documents 3mL of water into the 80mg vial, another 2mL: 26.7mg per mL versus 40mg per mL, a 50% dose divergence on the same vial.

The status: not FDA approved; all four sat on the FDA's Category 2 risk list until withdrawn by their nominators, and three return to the advisory agenda July 23 to 24, 2026. Ratios vary by vendor; in our read, that is the risk.

The calculator

How it works: drop in a vial size, a water amount, a syringe type, and a dose in milligrams. It returns the concentration, the volume, and the unit reading for the whole blend.

Units converter

Converts the numbers you type. It does not recommend a dose.

Vial amount mg Bacteriostatic water mL Syringe type Dose you want to convert mg

Concentration10 mg per mL

Volume to draw0.1 mL

Reads as10 units

Arithmetic only. Check the result against your own vial, your own reconstitution, and your own syringe before you trust any unit count.

On this page

Short answer Calculator Reported use What's in a KLOW vial? The 2mL vs 3mL split How the units math works How many units is 4mg? What's not known yet? The safety picture How this page is sourced The disclaimer

Community reports, not a protocol

What do users report running?

The source: this section is what the ranking protocol pages describe, in their own numbers, checked 19 July 2026.

The common vial: an 80mg blend, most often labeled GHK-Cu 50mg, KPV 10mg, BPC-157 10mg, TB-500 10mg.

The reported draw:

4mg total blend per injection
2.5mg of GHK-Cu inside that draw
500mcg each of BPC-157, TB-500, and KPV

The published ladders: the protocol pages post 2, 4, 6, and 8mg total-blend amounts, with no trial behind any rung.

Reported side effects: injection-site redness said to fade within 30 to 60 minutes, mild warmth or flushing, nausea in the first 2 to 3 injections, occasional headache, slight drowsiness. Community-attributed, none of it trial-verified.

Even the pages concede it: one of the most detailed protocol pages states plainly that no human clinical trials exist for this combination.

Why people pick it: the pages pitch KLOW for repair plus inflammation plus gut, with the KPV piece as the differentiator from its sister blend GLOW. That positioning is their marketing copy, not evidence.

Component by component, cited

What is actually in a KLOW vial?

The honest starting point: zero published studies test this blend. What follows is what the evidence says about each component on its own, with the citations at the bottom.

BPC-157, 10mg on the common label

What it is: a pentadecapeptide, 15 amino acids, isolated from human gastric juice (Józwiak et al., 2025).

The evidence: almost entirely preclinical. Reviews describe positive healing signals across injury models, mostly in small rodent models, with efficacy yet to be confirmed in humans (Gwyer et al., 2019). Three small uncontrolled human pilots exist, 30 subjects analyzed in total, and they are covered in our BPC-157 guide.

The status: not approved by the FDA or other global regulators, for lack of sufficient human clinical studies, while being offered for sale on many websites (Józwiak et al., 2025).

TB-500, 10mg on the common label

What it is: a fragment, LKKTETQ, of thymosin beta-4, a naturally occurring repair peptide released by platelets after injury and tied to cell migration (Goldstein et al., 2012; FDA naming).

The evidence: the parent peptide has real human trials. A phase 2 trial of topical thymosin beta-4 in venous stasis ulcers randomized 73 patients across 8 European sites; safety was comparable to placebo, and about 25% of patients healed completely within 3 months at the 0.03% dose (Guarnera et al., 2010).

The gap: that trial used the full-length peptide, on skin, for wounds. For the injected fragment sold as TB-500, the FDA says it has not identified any human exposure data at all.

GHK-Cu, 50mg on the common label

What it is: a copper tripeptide complex, glycyl-l-histidyl-l-lysine bound to copper (Miller et al., 2006).

The evidence: the human randomized data is topical and underwhelming. In a 13-completer trial after laser resurfacing, topical GHK-Cu showed no statistically significant objective benefit over control (Miller et al., 2006).

The gap: the blend injects it. For injectable GHK-Cu, the FDA cites limited human data and flags immunogenicity and aggregation risks.

KPV, 10mg on the common label

What it is: the tripeptide tail of alpha-MSH, alpha-MSH(11-13), a melanocortin fragment.

The evidence: two mouse colitis models, where KPV reduced inflammatory infiltrates and, in one receptor-mutant strain, rescued every treated animal from death (Kannengiesser et al., 2008). The FDA says it has identified no human exposure data for KPV by any route.

Four evidence floors: one component with human trials on its parent, one with thin topical human data, one with preclinical data plus three small uncontrolled human pilots, and one with animal data only. None of it measures what happens when the four are combined in one vial.

peptides in the blend, on the common label

80mg

the common vial size across the ranking pages

published studies on the blend itself, PubMed, checked 19 July 2026

50%

dose divergence between the two documented reconstitutions

PubMed search and live protocol pages, checked 19 July 2026. Details in the sources section.

Is the 2mL mix the same as the 3mL mix?

The usual dodge: protocol pages pick one water volume and present it as settled. The live record shows two, and it does not agree with itself.

What one camp documents

The 3mL version: several ranking pages, including a vendor calculator and two dosage libraries, describe adding 3mL of bacteriostatic water to the 80mg vial. That makes 26.7mg per mL.

The stated logic: larger, easier-to-measure draws.

What the other camp documents

The 2mL version: another ranking page calls 2mL its standard dilution and builds its main conversion table on it. That makes 40mg per mL.

The twist: that same page documents the 3mL version too, in a second table, and a third camp posts 4mL, which is 20mg per mL.

What is resolvable: the arithmetic. Both mixes are the same 80mg of blend in different amounts of water, and both are honestly labeled on the pages that post them.

What is not: which mix any given vial actually got. The same 10 units is 4.0mg on one documented mix and 2.67mg on the other, a 50% gap, and no page can tell you what was done to the vial in front of you.

We are not going to tell you which of those numbers is right for you, and neither should the camps.

The real question: in the end it is about your body, your risk tolerance, and a conversation with a doctor who knows your history. What we can give you is what the sources claim, why they disagree, and the math behind a dose; the rest is yours to work through with someone qualified.

How does the units math work?

The point: run this arithmetic once, in general terms, with no dose attached to you.

Example one: say an 80mg KLOW vial gets reconstituted with 2mL of bacteriostatic water. That's 40mg per mL, or 40,000mcg per mL.

The syringe side: the U-100 insulin syringe reads 100 units per mL, so each unit equals 1/100th of a mL, which at this concentration is 0.4mg. From there: 4mg of blend is 10 units, 2mg is 5 units, 8mg is 20 units.

Change one thing: reconstitute the same 80mg vial with 3mL instead of 2mL, the other documented version. Concentration drops to 26.7mg per mL.

What changes: each unit now equals 0.267mg instead of 0.4mg. The same 4mg of blend is now 15 units, not 10.

The forum trap: the "10 units" on one protocol page and the "15 units" on another can be the same 4mg, on two honestly documented mixes of the same vial.

Same 80mg KLOW vial, two documented reconstitutions, on a U-100 syringe

Water added	Concentration	1 unit equals	What the math works out to
2mL	40mg per mL (40,000mcg per mL)	0.4mg (400mcg)	4mg is 10 units, 2mg is 5 units, 8mg is 20 units
3mL	26.7mg per mL	0.267mg (267mcg)	4mg is 15 units, not 10

Same vial, same blend, two published water volumes. The unit count moves; the milligrams do not.

Syringe scale, before any concentration math

Syringe	Units per mL	1 unit equals
U-100	100 units per mL	0.01mL
U-40	40 units per mL	0.025mL

At the same unit mark, the U-40 pulls 2.5x the drug the U-100 does.

The blend wrinkle: at the common 50/10/10/10 label split, a 4mg total draw carries 2.5mg of GHK-Cu and 500mcg of each other component. The units math converts the blend total; the ratio inside is the vendor's.

The other trap: the syringe scale itself. Insulin syringes read in units at two scales.

The two scales: U-100 holds 100 units per mL, one unit 0.01mL. U-40 holds 40 units per mL, one unit 0.025mL.

The 2.5x problem: draw on a U-40 with U-100 numbers in mind and each unit is 2.5 times the volume you think it is. Same vial, same concentration, same "10 units" on the barrel.

Before the concentration argument, check which syringe is in your hand.

Both halves: that is the whole units-versus-mg problem, and for a blend it is worse. The syringe never lies. It does not know your concentration, your blend, or its own scale; you do.

How many units is 4mg of KLOW?

The short answer: it depends which documented mix is in front of you. At 40mg per mL (the 2mL version), 4mg reads as 10 units on a U-100 syringe. At 26.7mg per mL (the 3mL version), the same 4mg reads as 15 units.

The rule: there is no universal units number for any milligram amount, and for KLOW there is not even one water volume the internet agrees on. Concentration first, syringe type second, then the arithmetic, or run the numbers in the calculator above.

What's not known yet?

The status: KLOW is not FDA approved. Neither is any component in it for general use, and the blend could not be: there is no single manufacturer, no fixed ratio, and no trial to file.

The regulator's file: all four components appear on the FDA's "nominated but withdrawn" list, pulled from the Category 2 significant-safety-risk list by their nominators, checked 20 July 2026 against a page the FDA dates 22 April 2026. The agency's earlier file said it had identified no human exposure data at all for TB-500 and KPV, cited limited human data for injectable GHK-Cu, and reported no, or only limited, safety information for BPC-157. New nominations for BPC-157, KPV, and TB-500 go back before the advisory committee on July 23 to 24, 2026.

The real gaps:

No published study of the blend itself, at any dose. PubMed returns zero results, checked 19 July 2026.
No verified data on how the four components interact when combined.
No fixed ratio: the 50/10/10/10 label is the most documented, not a standard, and ratios vary by vendor.

Anyone who tells you they know better is guessing.

The biggest gap: in our read, one gap matters more than any milligram figure. A grey-market blend vial comes with no independent verification of what is actually in it.

All taken on trust: identity, ratio, purity, sterility, and the real labeled milligrams.

The quiet one: a mislabeled vial breaks every units calc above, twice over. The math needs the right milligrams and the right ratio.

The real worry: that is not a dosing question, a sourcing question squared, and with a blend, it is the only thing we would lose sleep over.

How this page is sourced

No secondary summaries: every research figure above comes straight from the cited papers' abstracts, and the regulatory claims from the FDA's own pages. Not lifted from a secondary summary.

The seven sources: six papers and one regulator page, with DOIs, PubMed IDs, and the FDA URL. Pull them yourself, and check the decode against them.

The standard: the sourcing and citation-verification standard for the site lives on the methodology page. Corrections to any number here happen there first.

Last reviewed: 19 July 2026.

1
Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. doi:10.3390/ph18020185. PMID 40005999.
2
Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8. PMID 30915550.
3
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta-4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793. PMID 22074294.
4
Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-212. doi:10.1111/j.1749-6632.2010.05490.x. PMID 20536470.
5
Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. doi:10.1002/ibd.20334. PMID 18092346.
6
Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. doi:10.1001/archfaci.8.4.252. PMID 16847171.
7
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2), including the "nominated but withdrawn" list. Content current as of 22 April 2026. Accessed 20 July 2026. fda.gov/drugs/human-drug-compounding.

The disclaimer

Every page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice.

It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.